Bart Klein was at the forefront of ProQR's Axiomer® RNA editing technology development. This platform technology makes it possible to use the cells own machinery to reverse mutations that cause a genetic disease. Read the interview.
… Always excited about RNA therapies He is one of the founders of ProQR, but even … that Gerard Platenburg was involved in the development of RNA therapies. Even so, after decades of working on them he … as they say. Gerard Platenburg What made you pursue RNA therapy as a potential treatment for these diseases? …
… Biasutto, sepofarsen captain. Her work, developing a novel RNA therapy for Leber congenital amaurosis 10, has progressed … and – eventually – blindness. ProQR is developing a novel RNA therapy for LCA10 patients, called sepofarsen. The …
ProQR to host a conference call to discuss the top-line results of the Phase 2/3 Illuminate clinical trial of investigational RNA therapy sepofarsen in CEP20-mediated LCA10.
… “We have started testing sepofarsen, our investigational RNA therapy for Leber congenital amaurosis, in the organoids … diseases? Check out our pipeline of investigations RNA therapies. Hee Lam Chan, Principal Researcher …
